Key result
Cardiac manifestations in COPD are common and multifactorial, and the use of cardioselective beta-blockers in the management of cardiac disease in these patients is generally safe.
This review summarizes the complex interplay between COPD and cardiac diseases, emphasizing the safety of cardioselective beta-blockers and the need for comprehensive management of shared risk factors.
Answers are grounded in this paper and cite their sources.
Supports integrated cardiopulmonary care in COPD; leaves open randomized trials to confirm beta-blocker safety.
The cardiac manifestations of chronic obstructive pulmonary disease (COPD) are numerous. Impairments of right ventricular dysfunction and pulmonary vascular disease are well known to complicate the clinical course of COPD and correlate inversely with survival. The pathogenesis of pulmonary vascular disease in COPD is likely multifactorial and related to alterations in gas exchange and vascular biology, as well as structural changes of the pulmonary vasculature and mechanical factors. Several modalities currently exist for the assessment of pulmonary vascular disease in COPD, but right heart catheterization remains the gold standard. Although no specific therapy other than oxygen has been generally accepted for the treatment of pulmonary hypertension in this population, there has been renewed interest in specific pulmonary vasodilators. The coexistence of COPD and coronary artery disease occurs frequently. This association is likely related to shared risk factors as well as similar pathogenic mechanisms, such as systemic inflammation. Management strategies for the care of patients with COPD and coronary artery disease are similar to those without COPD, but care must be given to address their respiratory limitations. Arrhythmias occur frequently in patients with COPD, but are rarely fatal and can generally be treated medically. Use of beta-blockers in the management of cardiac disease, while a theoretical concern in patients with increased airway resistance, is generally safe with the use of cardioselective agents.
No takes yet. Share an insight, caveat, or question.
Falk et al. (2008) conducted a review in Chronic Obstructive Pulmonary Disease (COPD) and Cardiac Disease. Cardiac manifestations in COPD are common and multifactorial, and the use of cardioselective beta-blockers in the management of cardiac disease in these patients is generally safe.
Synapse has enriched 10 related papers. Consider them for comparative context: